{"id":"epo-alpha","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Thrombotic events (DVT, PE, stroke)"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Flu-like symptoms"},{"rate":"<1","effect":"Pure red cell aplasia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epo-alpha mimics the natural hormone erythropoietin, which regulates red blood cell formation in response to tissue hypoxia. By activating erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes proliferation, differentiation, and maturation of these cells into functional red blood cells. This mechanism is used therapeutically to treat anemia by increasing hemoglobin and hematocrit levels.","oneSentence":"Epo-alpha is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:19.798Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in cancer patients receiving chemotherapy"},{"name":"Anemia in patients with HIV infection"}]},"trialDetails":[{"nctId":"NCT00999583","phase":"PHASE3","title":"High Dose of Erythropoietin Analogue After Cardiac Arrest","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-10","conditions":"Comatose Survivors of Cardiac Arrest","enrollment":500},{"nctId":"NCT06490601","phase":"PHASE2","title":"Long Term Beta Thalassemia Treatment: Findings From The Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2022-04-01","conditions":"Fetal Hemoglobin, Beta-Thalassemia, Hemoglobinopathies","enrollment":30},{"nctId":"NCT01196715","phase":"PHASE3","title":"Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2010-11-01","conditions":"Myelodysplastic Syndrome","enrollment":360},{"nctId":"NCT03231085","phase":"NA","title":"Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2017-10-31","conditions":"Craniosynostosis","enrollment":100},{"nctId":"NCT02807558","phase":"PHASE2","title":"A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Syros Pharmaceuticals","startDate":"2016-09-20","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":155},{"nctId":"NCT03682536","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-01-02","conditions":"Myelodysplastic Syndromes","enrollment":363},{"nctId":"NCT05810311","phase":"PHASE2","title":"The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2025-06-01","conditions":"Diabetes Complications, Diabetes; Nephropathy (Manifestation)","enrollment":30},{"nctId":"NCT02251041","phase":"PHASE2","title":"Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-09","conditions":"Reperfusion Injury","enrollment":143},{"nctId":"NCT06466785","phase":"PHASE3","title":"A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Genexine, Inc.","startDate":"2024-01-25","conditions":"Anemia of Chronic Kidney Disease","enrollment":429},{"nctId":"NCT03446612","phase":"PHASE2","title":"Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-01-10","conditions":"Anaemia","enrollment":6},{"nctId":"NCT04432662","phase":"PHASE2","title":"Darbepoetin in Neonatal Encephalopathy Trial","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2021-05-28","conditions":"Neonatal Encephalopathy","enrollment":150},{"nctId":"NCT03071861","phase":"PHASE2","title":"Mild Encephalopathy in the Newborn Treated With Darbepoetin","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2017-12-01","conditions":"Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy Mild","enrollment":28},{"nctId":"NCT03339596","phase":"PHASE2","title":"Effects of Erythropoietin for Cognitive Side-effects of ECT","status":"COMPLETED","sponsor":"Martin Balslev Jørgensen","startDate":"2017-06-26","conditions":"ECT, Cognitive Impairment, Unipolar Depression","enrollment":60},{"nctId":"NCT03315897","phase":"PHASE2","title":"Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders","status":"COMPLETED","sponsor":"Lars Vedel Kessing","startDate":"2017-07-05","conditions":"Bipolar Disorder, Cognitive Impairment, Unipolar Depression","enrollment":103},{"nctId":"NCT05699109","phase":"","title":"Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-01-01","conditions":"Anemia of Chronic Kidney Disease, Chronic Renal Failure, Chronic Renal Failure Anemia","enrollment":127},{"nctId":"NCT05585658","phase":"PHASE1, PHASE2","title":"A Randomized, Double-blinded, Active Controlled Crossover Clinical Trial to Investigate PK, PD and Safety of GBPD002","status":"COMPLETED","sponsor":"Globe Biotech Limited","startDate":"2021-10-16","conditions":"Natural Blood and Blood Product Toxicity","enrollment":42},{"nctId":"NCT05080049","phase":"PHASE3","title":"Erythropoietin to Improve Critical Care Patient Outcomes","status":"UNKNOWN","sponsor":"University Hospital, Angers","startDate":"2022-01-28","conditions":"Anemia, Intensive Care","enrollment":42},{"nctId":"NCT05422755","phase":"","title":"The Clinical Study to Evaluate Immunogenicity of Epodion® in Anemia Associated With CKD Patients","status":"COMPLETED","sponsor":"PT. Daewoong Infion","startDate":"2019-09-30","conditions":"Chronic Kidney Disease (CKD)","enrollment":200},{"nctId":"NCT05373303","phase":"NA","title":"The Clinical Study for Evaluating The Safety And Efficacy Of Epodion®","status":"COMPLETED","sponsor":"PT. Daewoong Infion","startDate":"2019-11-07","conditions":"Chronic Kidney Disease (CKD)","enrollment":82},{"nctId":"NCT04959578","phase":"PHASE4","title":"Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Rufaida Mazahir","startDate":"2018-02-01","conditions":"Anemia of Chronic Kidney Disease","enrollment":50},{"nctId":"NCT02075970","phase":"PHASE2","title":"Optimized Erythropoietin (EPO) Treatment","status":"COMPLETED","sponsor":"John A Widness","startDate":"2014-06","conditions":"Neonatal Anemia","enrollment":62},{"nctId":"NCT00687258","phase":"PHASE2","title":"Evaluation Of A New Vitamin E-Bonded Membrane On Anemia And Oxidative Stress In End-Stage Renal Disease Patients","status":"COMPLETED","sponsor":"A. Manzoni Hospital","startDate":"2006-07","conditions":"Anemia","enrollment":20},{"nctId":"NCT00513240","phase":"PHASE1, PHASE2","title":"Erythropoetin Neuroprotection for Neonatal Cardiac Surgery","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-09","conditions":"Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries","enrollment":62},{"nctId":"NCT03408639","phase":"PHASE3","title":"Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2016-06-22","conditions":"Anemia in End-Stage Renal Disease","enrollment":156},{"nctId":"NCT00270478","phase":"PHASE1","title":"Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-12-21","conditions":"Sickle Cell Disease, Chronic Kidney Disease, Pulmonary Hypertension","enrollment":7},{"nctId":"NCT03521713","phase":"PHASE3","title":"To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)","status":"UNKNOWN","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-03-01","conditions":"Anemia of Chronic Kidney Disease","enrollment":214},{"nctId":"NCT02496377","phase":"NA","title":"Cross Iron (Comparative Randomized Oral Versus Systemic IRON)","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2014-08-29","conditions":"Allogenic Transfusion, Perioperative Anaemia, Knee Arthroplasty","enrollment":100},{"nctId":"NCT01868477","phase":"PHASE2","title":"Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-01-28","conditions":"Low and Int 1-risk Myelodysplastic Syndrome","enrollment":28},{"nctId":"NCT01695759","phase":"PHASE3","title":"Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.","status":"TERMINATED","sponsor":"Azidus Brasil","startDate":"2013-12","conditions":"Chronic Kidney Disease, Anemia","enrollment":92},{"nctId":"NCT02439697","phase":"NA","title":"A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-11","conditions":"Anemia, End Stage Renal Failure on Dialysis","enrollment":50},{"nctId":"NCT02031289","phase":"PHASE4","title":"Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2013-12","conditions":"Anemia, Iron Deficiency","enrollment":1003},{"nctId":"NCT00661505","phase":"PHASE3","title":"A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05-14","conditions":"Anemia","enrollment":132},{"nctId":"NCT03286712","phase":"PHASE4","title":"The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"National Kidney and Transplant Institute, Philippines","startDate":"2015-10","conditions":"Chronic Kidney Disease, Anemia, Complication of Peritoneal Dialysis","enrollment":30},{"nctId":"NCT02049346","phase":"PHASE4","title":"Comparison Among Erythropoietin Stimulating Agents","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2012-03","conditions":"Anemia of End Stage Renal Disease","enrollment":327},{"nctId":"NCT01417377","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-05-31","conditions":"Anemia","enrollment":22},{"nctId":"NCT00248339","phase":"PHASE3","title":"Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2002-05","conditions":"Hepatitis C","enrollment":150},{"nctId":"NCT00286182","phase":"PHASE2","title":"Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)","status":"COMPLETED","sponsor":"Mathew S. Maurer","startDate":"2007-07","conditions":"Anemia","enrollment":56},{"nctId":"NCT01383460","phase":"PHASE3","title":"Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2011-07","conditions":"Acute on Chronic Hepatic Failure","enrollment":55},{"nctId":"NCT00842621","phase":"","title":"Long Term Effects of Erythrocyte Lysis","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2009-03","conditions":"Sickle Cell Disease, Hemolytic Anemia","enrollment":390},{"nctId":"NCT00144755","phase":"PHASE3","title":"R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2003-12","conditions":"Diffuse Large Cell Lymphoma","enrollment":600},{"nctId":"NCT01538771","phase":"PHASE2","title":"Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2009-11","conditions":"Myocardial Infarction","enrollment":80},{"nctId":"NCT00704652","phase":"","title":"Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2008-05","conditions":"Diabetic Retinopathy","enrollment":5},{"nctId":"NCT02181348","phase":"PHASE1, PHASE2","title":"Effect of Vitamin E Supplementation on Hemoglobin Levels in Healthy Adults","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2008-11","conditions":"Anemia","enrollment":357},{"nctId":"NCT00267007","phase":"PHASE2","title":"A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-06","conditions":"Peripheral Neuropathy, Chemotherapy-induced","enrollment":32},{"nctId":"NCT00511901","phase":"PHASE4","title":"Prevalence and Treatment of Anemia in Rehabilitation Patients","status":"TERMINATED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2005-11","conditions":"Anemia","enrollment":22},{"nctId":"NCT01384565","phase":"PHASE3","title":"G-CSF and Erythropoetin in Survival of Patients With Decompensated Liver Disease","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2011-07","conditions":"Chronic Liver Disease","enrollment":55},{"nctId":"NCT00526747","phase":"","title":"Erythropoietin Resistance in Anemia of Chronic Kidney Disease","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-08","conditions":"Anemia, Kidney Failure, Erythropoietin","enrollment":32},{"nctId":"NCT00524901","phase":"PHASE2","title":"Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2007-09","conditions":"CABG, Coronary Artery Disease","enrollment":10},{"nctId":"NCT01758861","phase":"PHASE2","title":"Effect of Erythropoietin on the Incidence of Acute Kidney Injury Following Complex Valvular Heart Surgery","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-07","conditions":"Acute Kidney Injury","enrollment":98},{"nctId":"NCT00944684","phase":"PHASE2","title":"High Dose Ribavirin in the Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"University of Bern","startDate":"2007-11","conditions":"Chronic Hepatitis C","enrollment":32},{"nctId":"NCT01392612","phase":"PHASE4","title":"Erythropoietin and Platelet Activation Markers","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2006-11","conditions":"Thrombosis, Hypertension","enrollment":12},{"nctId":"NCT00719498","phase":"PHASE3","title":"Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)","status":"COMPLETED","sponsor":"Janssen Cilag S.A.S.","startDate":"2003-11","conditions":"Resuscitation, Cardiopulmonary, Cardiac Arrest","enrollment":20},{"nctId":"NCT00446576","phase":"PHASE3","title":"The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease","status":"COMPLETED","sponsor":"Janssen-Cilag B.V.","startDate":"1999-11","conditions":"Anemia","enrollment":176},{"nctId":"NCT00425698","phase":"PHASE2, PHASE3","title":"Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2007-02","conditions":"Kidney Transplantation","enrollment":88},{"nctId":"NCT00691613","phase":"NA","title":"Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2010-07","conditions":"Ischemia-Reperfusion Injury, Myocardial Infarction","enrollment":12},{"nctId":"NCT00557817","phase":"PHASE2, PHASE3","title":"Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)","status":"COMPLETED","sponsor":"University of Liege","startDate":"2004-03","conditions":"Hematological Malignancies","enrollment":125},{"nctId":"NCT00399269","phase":"PHASE3","title":"Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure","status":"COMPLETED","sponsor":"Cadila Pharnmaceuticals","startDate":"2006-12","conditions":"Anemia","enrollment":100},{"nctId":"NCT00234143","phase":"PHASE2, PHASE3","title":"Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)","status":"UNKNOWN","sponsor":"St. Bartholomew's Hospital","startDate":"2004-10","conditions":"Myelodysplastic Syndromes","enrollment":360},{"nctId":"NCT00443339","phase":"PHASE2","title":"Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)","status":"UNKNOWN","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2006-12","conditions":"Myelodysplastic Syndromes","enrollment":99},{"nctId":"NCT00189371","phase":"PHASE3","title":"Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum","status":"TERMINATED","sponsor":"AGO Study Group","startDate":"2004-02","conditions":"Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, Platinum Sensitve Relapse, Anemia","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Epo-alpha","genericName":"Epo-alpha","companyName":"Janssen Cilag S.A.S.","companyId":"janssen-cilag-s-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epo-alpha is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in cancer patients receiving chemotherapy, Anemia in patients with HIV infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}